CELLFOOD DNA/RNA is a landmark new formula that combines the benefits of CELLFOOD with powerful proprietary laser technology. Delivering highly bioactive nucleic acid elements with synergistic cofactors, this formula can help rebuild and boost the function of every cell in the body.

References:

Grimble GK. Dietary nucleotides and gut mucosal defense. Gut 1994; Supplement 1: S46-S51.

Rigby PG. The effect of "exogenous" RNA on the improvement of syngeneic tumor immunity. 
Cancer Research 1971; 31: 4-6.

Savaiano DA, Ho CY, Chu V, Clifford AJ. Metabolism of orally and intravenously administered purines 
in rats. J Nutr 1981; 110: 1793-1804.

Uauy R, Quan R, Gil A. Role of nucleotides in intestinal development and repair:  implications for infant nutrition. J Nutr 1994; 124: 1436S-41S.

Bowles JT. The evolution of aging: a new approach to an old problem of biology. Medical Hypotheses 1998; 51: 179-221.

Agteresch HJ, et al. Adenosine triphosphate: established and potential clinical applications. Drugs 1999; 58(2): 211-232.

Gur S, Ozturk B. Altered relaxant response to adenosine and adenosine 5'-triphosphate in the corpus cavernosum from men and rats with diabetes. Pharmacology 2000; 60:
105-112.

Bohoun C, Caillard L. S-adenosyl-methionine in human blood. Clinica Chimica Acta 1971; 33: 256.

Borsook H, et al. The biochemical basis of betaine-glycocyamine therapy. Annals of Western Medicine 
and Surgery 1951; 5(10): 825-9.

Borsook H, et al. Treatment of cardiac decompensation with betaine and glycocyamine.
Annals of Western Medicine and Surgery 1951; 5(10): 830-55.

Boushey CJ, et al. Quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274:
1049-57.

Cooney C. Methyl magic: maximum health through methylation. Andrews McNeil Publishing: 
Kansas City, 1999.

Cooney C. Are somatic cells inherently deficient in methylation metabolism? A proposed mechanism for DNA methylation loss, senescence and aging. Growth, Development, and Aging 1993; 57(4): 261-73.

Frankel P. The methylation miracle: unleash your body's natural source of SAMe. St. Martin's Mass 
Market Paper 1999

Kishi T, et al. Effect of betaine on SAMe levels in the cerebrospinal fluid of a patient with
methylenetetrahydrofolate reductase deficiency and peripheral neuropathy. Journal of
Inherited Metabolic Disease 1994; 17(5): 560-6.

Lee MA, et al. Study on homocysteine's role in atherosclerosis. Proceedings of the National Academy 
of Sciences 1994; 91(14): 6369-73.

McCully KS. The homocysteine revolution: medicine for the next millennium. Keats Publishing: 
Los Angeles, California, 1999.

McKully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. American Journal of Pathology 1969; 56: 111-28.

Morrison LM. Use of betaine-lipotropic combinations in clinical practice. Geriatrics 1953;
1953; 8: 649-55.

Nygard O, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. 
New England Journal of Medicine 1997; 337: 230-6.

Nygard O, et al. Total plasma homocysteine and cardiovascular risk profile (the Hordaland
homocysteine study). JAMA 1995; 274(19): 1526-33.

Perry IJ, et al. Prospective study of total serum homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346(1): 395-8.

Ray J. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. 
Arch Intern Med 1998; 158: 2101-6.

Wainfan E, et al. Methyl Groups in carcinogenesis: effects on DNA methylation and gene expression. 
Cancer Research 1992; 52(Suppl.7): 2071S- 7S.

Wendel U, et al. Betaine in the treatment of homocystinuria due to
5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr 1984; 142: 147-50.

Wu LL, et al. Plasma homocysteine as a risk factor for early familial coronary artery disease. 
Clin Chem 1994; 40: 551-2.